BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2023; 11(3): 566-575 [PMID: 36793628 DOI: 10.12998/wjcc.v11.i3.566]
URL: https://www.wjgnet.com/2307-8960/full/v11/i3/566.htm
Number Citing Articles
1
Yang Yang, Yuxin Zhang, Ran Zhang, Manna Li, Hongping Wan, Wenjun Yan, Kaiping Luo, Qipeng Huang, Daijin Ren, Gaosi Xu. Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stageEuropean Journal of Pharmacology 2025; 1000: 177739 doi: 10.1016/j.ejphar.2025.177739
2
L.D. Denova, I.V. Krasiuk. A clinical case of primary membranous glomerulonephritis with nephrotic syndrome and resistance to standard treatmentKIDNEYS 2023; 12(4): 211 doi: 10.22141/2307-1257.12.4.2023.431
3
Yang Yang, Kaiqi Cheng, Gaosi Xu. Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelinesEuropean Journal of Pharmacology 2024; 982: 176928 doi: 10.1016/j.ejphar.2024.176928
4
Muhammad Umar Ahsan, Arooj Tabassum, Kinza Naseem, Imran Bin Zahid. Obinutuzumab: a new frontier in the treatment of refractory idiopathic membranous nephropathyInternational Urology and Nephrology 2025;  doi: 10.1007/s11255-025-04500-7